openPR Logo
Press release

Warm Autoimmune Hemolytic Anemia (WAIHA) Market Size 2023: Epidemiology, Industry Trends and Forecast by 2033

06-21-2023 02:52 PM CET | Health & Medicine

Press release from: IMARC Group

Warm Autoimmune Hemolytic Anemia (WAIHA) Market Size 2023:

IMARC Group has recently released a report titled "Warm Autoimmune Hemolytic Anemia (WAIHA) Market: Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast (2023-2033)" that presents a comprehensive assessment of the warm autoimmune hemolytic anemia (WAIHA) market size. The report provides an extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth analysis of the disease landscape, market size, and growth trends. Furthermore, the report offers an analysis of competitors, regional markets, and recent advancements in the global market. It also sheds light on crucial segments and market drivers, along with challenges faced by industry players. This report is a valuable resource for stakeholders who want to gain valuable insights into the warm autoimmune hemolytic anemia (WAIHA) market.

Warm autoimmune hemolytic anemia (WAIHA) refers to a rare autoimmune condition that triggers the immune system to destroy the body's red blood cells (RBCs). The symptoms of this disorder typically include fatigue, weakness, shortness of breath, jaundice, rapid heartbeat, dark urine, an enlarged spleen, etc. As the disease progresses, an individual can also experience an acute hemolytic crisis characterized by the sudden onset of anemia, which can be life-threatening. The diagnosis of WAIHA involves a combination of physical examination, medical history review, complete blood count test, bone marrow biopsy, ultrasound, and CT scan.

Request a Free Sample Report: https://www.imarcgroup.com/warm-autoimmune-hemolytic-anemia-market/requestsample

The increasing incidence of variations in genes that control immune system function is primarily driving the warm autoimmune hemolytic anemia (WAIHA) market. In line with this, the rising cases of numerous triggering factors, including bacterial infections, autoimmune diseases like rheumatoid arthritis and lupus, fluctuations in hormones, etc., are also augmenting the market growth. Furthermore, the growing employment of intravenous immunoglobulin (IVIG) treatment, in which high levels of immunoglobin are infused into the bloodstream to control the autoimmune response and minimize the destruction of RBCs, is creating a positive outlook for the market.

Additionally, the inflating utilization of supportive therapies, such as folic acid supplementation, erythropoietin, iron supplementation, etc., to manage the symptoms of anemia and enhance the quality of life in patients is acting as another significant growth-inducing factor. Besides this, the rising popularity of rituximab as a means of targeting and eliminating B cells in individuals who are unresponsive or intolerant to corticosteroids or immunosuppressants is anticipated to propel the warm autoimmune hemolytic anemia (WAIHA) market during the forecasted period.

Report Period:

Base Year: 2022
Historical Period: 2017-2022
Market Forecast: 2023-2033

Countries Included:

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the warm autoimmune hemolytic anemia (WAIHA) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the warm autoimmune hemolytic anemia (WAIHA) market
Reimbursement scenario in the market
In-market and pipeline drugs
In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Regulatory Status

Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/request?type=report&id=7180&flag=C

Key Questions Answered in this Report:

How has the warm autoimmune hemolytic anemia (WAIHA) market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
What was the country-wise size of the warm autoimmune hemolytic anemia (WAIHA) market across the seven major markets in 2022 and what will it look like in 2033?
What is the growth rate of the warm autoimmune hemolytic anemia (WAIHA) market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Other Reports by IMARC group

Nasal Polyps Market Report: https://www.imarcgroup.com/nasal-polyps-market

Leiomyosarcoma Market Report: https://www.imarcgroup.com/leiomyosarcoma-market

Cystinuria Market Report: https://www.imarcgroup.com/cystinuria-market

Traveler's Diarrhea Market Report: https://www.imarcgroup.com/travelers-diarrhea-market

How This Report Can Help You:

The report on warm autoimmune hemolytic anemia (WAIHA) market presents a comprehensive overview and analysis of the epidemiology and market for this condition in the seven major markets (7MM): the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

With insights into both current and emerging therapies in the 7MM, this report offers valuable information for businesses seeking to understand trends and opportunities within the warm autoimmune hemolytic anemia (WAIHA) market.

The warm autoimmune hemolytic anemia (WAIHA) market report covers historical and forecasted market data, including epidemiology scenario, providing a reliable and informative resource for developing effective business strategies in 7MM.

Our report on the warm autoimmune hemolytic anemia (WAIHA) market can help businesses stay abreast of the trends and drivers, gain a competitive edge and drive success.

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Warm Autoimmune Hemolytic Anemia (WAIHA) Market Size 2023: Epidemiology, Industry Trends and Forecast by 2033 here

News-ID: 3095954 • Views:

More Releases from IMARC Group

GCC Pet Food Market Size is Expected to Reach USD 422.9 Million By 2033 | CAGR: 5.3%
GCC Pet Food Market Size is Expected to Reach USD 422.9 Million By 2033 | CAGR: …
GCC Pet Food Market Overview Market Size in 2024: USD 266.2 Million Market Size in 2033: USD 422.9 Million Market Growth Rate 2025-2033: 5.3% According to IMARC Group's latest research publication, "GCC Pet Food Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", the GCC pet food market size was valued at USD 266.2 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 422.9 Million by 2033, exhibiting a
GCC Residential Real Estate Market Size to Worth USD 147.77 Billion by 2033 | With a 7.50% CAGR
GCC Residential Real Estate Market Size to Worth USD 147.77 Billion by 2033 | Wi …
GCC Residential Real Estate Market Overview Market Size in 2024: USD 73.31 Billion Market Size in 2033: USD 147.77 Billion Market Growth Rate 2025-2033: 7.50% According to IMARC Group's latest research publication, "GCC Residential Real Estate Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", the GCC residential real estate market size was valued at USD 73.31 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 147.77 Billion by
GCC Drones Market Size to Surpass USD 2,005.3 Million by 2033 | With a 13.3% CAGR
GCC Drones Market Size to Surpass USD 2,005.3 Million by 2033 | With a 13.3% CAG …
GCC Drones Market Overview Market Size in 2024: USD 588.2 Million Market Size in 2033: USD 2,005.3 Million Market Growth Rate 2025-2033: 13.3% According to IMARC Group's latest research publication, "GCC Drones Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", The GCC drones market size was valued at USD 588.2 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 2,005.3 Million by 2033, exhibiting a growth rate of
Medical Imaging Market to Surpass USD 70.8 Billion by 2033, at a CAGR of 5.03%
Medical Imaging Market to Surpass USD 70.8 Billion by 2033, at a CAGR of 5.03%
Market Overview: The medical imaging market is experiencing rapid growth, driven by Growing Burden of Chronic and Age-Related Diseases, Expansion of Government-Funded Health Infrastructure and Technological Advancements in Imaging Modalities. According to IMARC Group's latest research publication, "Medical Imaging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", The global medical imaging market size reached USD 44.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach

All 5 Releases


More Releases for WAIHA

Warm Autoimmune Hemolytic Anemia (wAIHA) Market is expected to reach USD 600 mil …
Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disorder where the immune system produces autoantibodies that target and destroy red blood cells at body temperature. This leads to anemia, fatigue, jaundice, and, in severe cases, life-threatening complications. Despite being one of the most common forms of autoimmune hemolytic anemia, wAIHA remains underdiagnosed and undertreated. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71541 Historically, treatment relied heavily on corticosteroids and
Warm Autoimmune Hemolytic Anemia (wAIHA) Clinical and Non-Clinical Studies, Key …
Warm Autoimmune Hemolytic Anemia (wAIHA) companies are Fostamatinib, Immunovant Sciences GmbH, Apellis Pharmaceuticals, Inc., Bioverativ, and others. Warm Autoimmune Hemolytic Anemia (wAIHA) Pipeline constitutes 5+ key companies continuously working towards developing 5+ Warm Autoimmune Hemolytic Anemia (wAIHA) treatment therapies, analyzes DelveInsight. Warm Autoimmune Hemolytic Anemia (wAIHA) Overview: Warm antibody hemolytic anemia is a rare autoimmune condition in which the immune system mistakenly targets and destroys healthy red blood cells, leading to their early
Warm Autoimmune Hemolytic Anemia WAIHA Market Sector Analysis, Market Trends, an …
The Warm Autoimmune Hemolytic Anemia (WAIHA) Market is estimated to be valued at USD 4.72 Billion in 2024 and is expected to reach USD 7.26 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031. Latest Report, titled "Warm Autoimmune Hemolytic Anemia WAIHA Market" Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031, by CoherentMI offers a comprehensive analysis of the industry, which comprises
Warm Autoimmune Hemolytic Anemia WAIHA Market Industry Size, Trends, and Growth …
A new Report by CoherentMI Market Reports, titled "Warm Autoimmune Hemolytic Anemia WAIHA Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031,"" offers a comprehensive analysis of the industry, which comprises insights on the Warm Autoimmune Hemolytic Anemia WAIHA market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. The Warm Autoimmune Hemolytic Anemia (WAIHA) Market is estimated to be valued at USD 4.72
Warm Autoimmune Hemolytic Anemia (WAIHA) Market
The Global Warm Autoimmune Hemolytic Anemia (WAIHA) Market is projected to exhibit a high CAGR during the forecast period of 2023-2030. WAIHA, which accounts for 60-70% of autoimmune hemolytic anemia (AIHA) cases, is primarily caused by autoantibodies targeting immunoglobulin G (IgG), leading to red blood cell destruction. Market Dynamics: Diagnostic Advancements: Enhanced Laboratory Techniques: Developments in diagnostic laboratory methods, such as flow cytometry and serologic assays, have improved the accuracy and timeliness of
Warm Autoimmune Hemolytic Anemia (WAIHA) Market to Reach US$ 3,196.6 Million by …
The newly published report by IMARC Group, titled "Warm Autoimmune Hemolytic Anemia (WAIHA) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the warm autoimmune hemolytic anemia (WAIHA) market size. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the